Comments on cochrane review on direct-acting antivirals for hepatitis C

Anna S. Lok; Raymond T. Chung; Hugo E. Vargas; Arthur Y. Kim; Susanna Naggie; William G. Powderly

doi:10.1002/hep.29366

Comments on cochrane review on direct-acting antivirals for hepatitis C

Anna S. Lok, Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, William G. Powderly

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1016-1019
Number of pages	4
Journal	Hepatology
Volume	66
Issue number	4
DOIs	https://doi.org/10.1002/hep.29366
State	Published - Oct 2017

Access to Document

10.1002/hep.29366

Cite this

@article{989247e0215d41ac87f9d333b824a10f,

title = "Comments on cochrane review on direct-acting antivirals for hepatitis C",

author = "Lok, {Anna S.} and Chung, {Raymond T.} and Vargas, {Hugo E.} and Kim, {Arthur Y.} and Susanna Naggie and Powderly, {William G.}",

note = "Funding Information: Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29366 Potential conflict of interest: Dr. Lok received grants from Bristol-Myers Squibb and Gilead. Dr. Chung received grants from Gilead, AbbVie, Janssen, Merck, and Bristol-Myers Squibb. Dr. Vargas received grants from AbbVie, Gilead, and Merck. Dr. Naggie received grants from Gilead, AbbVie, and Merck. Dr. Powderly consults and received grants from Merck. He consults for Gilead.",

year = "2017",

month = oct,

doi = "10.1002/hep.29366",

language = "English",

volume = "66",

pages = "1016--1019",

journal = "Hepatology",

issn = "0270-9139",

number = "4",

}

TY - JOUR

T1 - Comments on cochrane review on direct-acting antivirals for hepatitis C

AU - Lok, Anna S.

AU - Chung, Raymond T.

AU - Vargas, Hugo E.

AU - Kim, Arthur Y.

AU - Naggie, Susanna

AU - Powderly, William G.

N1 - Funding Information: Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29366 Potential conflict of interest: Dr. Lok received grants from Bristol-Myers Squibb and Gilead. Dr. Chung received grants from Gilead, AbbVie, Janssen, Merck, and Bristol-Myers Squibb. Dr. Vargas received grants from AbbVie, Gilead, and Merck. Dr. Naggie received grants from Gilead, AbbVie, and Merck. Dr. Powderly consults and received grants from Merck. He consults for Gilead.

PY - 2017/10

Y1 - 2017/10

UR - http://www.scopus.com/inward/record.url?scp=85028344563&partnerID=8YFLogxK

U2 - 10.1002/hep.29366

DO - 10.1002/hep.29366

M3 - Comment/debate

C2 - 28714142

AN - SCOPUS:85028344563

SN - 0270-9139

VL - 66

SP - 1016

EP - 1019

JO - Hepatology

JF - Hepatology

IS - 4

ER -

Comments on cochrane review on direct-acting antivirals for hepatitis C

Access to Document

Other files and links

Cite this